NASDAQ:INGN - Inogen Stock Price, Forecast & News

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen Inc (NASDAQ:INGN) issued its quarterly earnings data on Tuesday, February, 25th. The medical technology company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of $0.11 by $0.17. The medical technology company had revenue of $78.92 million for the quarter, compared to analysts' expectations of $90.11 million. Inogen had a return on equity of 7.14% and a net margin of 5.79%. The company's revenue for the quarter was down 8.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.44 earnings per share. View Inogen's Earnings History.

Inogen is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Inogen.

Inogen issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $385-400 million, compared to the consensus revenue estimate of $403.47 million.

7 equities research analysts have issued 12-month price objectives for Inogen's shares. Their forecasts range from $45.00 to $90.00. On average, they anticipate Inogen's share price to reach $62.00 in the next year. This suggests a possible upside of 33.8% from the stock's current price. View Analyst Price Targets for Inogen.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inogen.

Media stories about INGN stock have trended very negative recently, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Inogen earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the medical technology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Inogen.

Inogen saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 2,370,000 shares, an increase of 10.7% from the January 30th total of 2,140,000 shares. Based on an average daily volume of 341,500 shares, the short-interest ratio is presently 6.9 days. Approximately 13.0% of the shares of the stock are sold short. View Inogen's Current Options Chain.

Some companies that are related to Inogen include Wound Management Technologies (WNDM), Wright Medical Group (WMGI), Avanos Medical (AVNS), Establishment Labs (ESTA), RTI Surgical (RTIX), Invacare (IVC), Sientra (SIEN), Lakeland Industries (LAKE), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Histogenics (HSGX), Allied Healthcare Products (AHPI), NanoVibronix (NAOV), Bionik Laboratories (BNKL) and Rewalk Robotics (RWLK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), First Solar (FSLR), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU) and Dynavax Technologies (DVAX).

Inogen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (4.44%), AQR Capital Management LLC (3.92%), State Street Corp (3.00%), New York State Common Retirement Fund (2.25%), Rockefeller Capital Management L.P. (1.28%) and Riverbridge Partners LLC (1.23%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.

INGN stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Renaissance Technologies LLC, Cubist Systematic Strategies LLC, UBS Asset Management Americas Inc., State Street Corp, Marshall Wace LLP, American International Group Inc. and AlphaCrest Capital Management LLC. View Insider Buying and Selling for Inogen.

INGN stock was acquired by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Point72 Asset Management L.P., Beacon Investment Advisory Services Inc., Tamarack Advisers LP, Great West Life Assurance Co. Can, Jane Street Group LLC, Pinebridge Investments L.P. and Oxford Asset Management LLP. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch and Loren L Mcfarland. View Insider Buying and Selling for Inogen.

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INGN stock can currently be purchased for approximately $46.35.

Inogen has a market capitalization of $1.02 billion and generates $361.94 million in revenue each year. The medical technology company earns $51.85 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,099 workers across the globe.View Additional Information About Inogen.

The official website for Inogen is http://www.inogen.com/.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]